Form 4: Hologic Director Christiana Stamoulis Executes Option Exercise and Stock Sale Under 10b5-1 Plan

Director Christiana Stamoulis exercised stock options and sold shares of Hologic Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 17, 2024, Christiana Stamoulis, a director of Hologic Inc., executed a transaction involving the company's stock.
• Stamoulis exercised 9,039 non-qualified stock options at a price of $26.74 per share.
• Simultaneously, Stamoulis sold 9,039 shares of common stock at $79.5 per share.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on February 16, 2024.
• Following these transactions, Stamoulis directly owns 45,472 shares of Hologic Inc. common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing simply reports routine stock transactions under a pre-existing trading plan. There is no indication of positive or negative implications for the company's performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading.

Industry Context

Executive stock transactions are common and closely monitored, with 10b5-1 plans providing a legal framework for insiders to trade company stock while avoiding accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice among corporate executives to manage their stock holdings in a compliant manner.
• Comparable companies such as Intuitive Surgical and Abbott Laboratories also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders as they are part of a pre-planned trading strategy.

Key Dates